CMS Sofia has advised Global Biomet on the acquisition of the Resen photovoltaic project, with installed capacity of 5 MW, from Austria's Novasolar GmbH. The deal, which is valued at almost EUR 10 million, closed on September 16, 2019.
CMS Hungary has advised Balbec Capital and Momentum Credit Zrt, a Hungarian joint venture owned by Balbec Capital and the APS Group, on the purchase of MKB Bank Nyrt’s non-performing retail mortgage loan portfolio, secured mostly by residential mortgages. MKB Bank was advised by HBK Partners on the transaction.
Jones Day has advised Societe Generale in connection with the sale of its majority stake in the share capital of Societe Generale Montenegro, a company listed on the Montenegrin Stock Exchange, to OTP Bank Nyrt. Schoenherr advised Societe Generale on matters of Montenegrin law, while CMS advised OTP.
It has been over a year since the European Union’s General Data Protection Regulation became mandatory across Europe, marking a seismic shift in the way that companies collect, process, and handle personal data. Countries across the European Union and beyond have adapted their national laws to meet the requirements of the GDPR – with many introducing local derogations as permitted by the GDPR.
It is no secret that North Macedonia is facing the issue of usage of products for plant protection which often fail to meet legal standards. Namely, Macedonian manufacturers producing agricultural products for human and animal nutrition often use unauthorized products which fail to meet safety criteria and may have suspicious origins. Although this issue is not as widely-discussed as air pollution in North Macedonia, it contributes significantly to the existing environmental pollution problem and has a huge impact on the health of plants, people, and the environment.
Use of Artificial intelligence is growing rapidly. Some of the world’s largest industries are using AI as frequently as any other business tool. Still, there are industries which seem to be more risk averse. Pharma integrates AI at the rate of 31% in the service operations sector, 31% in the product/service development sector, and 27% in the marketing sector. Does that mean that pharma is lagging in implementing AI?